Wright Medical Group N.V. reported unaudited consolidated earnings results for the second quarter and six months ended June 25, 2017. For the quarter, the company reported net sales of $179,693,000 against $170,716,000 a year ago. Operating loss was $8,793,000 against $34,368,000 a year ago. Loss from continuing operations before income taxes was $20,575,000 against $45,331,000 a year ago. Net loss from continuing operations was $20,960,000 against $42,031,000 a year ago. Net loss was $41,162,000 against $229,360,000 a year ago. Net loss from continuing operations per basic and diluted share was $0.20 against $0.41 a year ago. Net loss per basic and diluted share was $0.39 against $2.23 a year ago. Adjusted non-GAAP loss was $7,640,000 against $11,311,000 a year ago. Adjusted non-GAAP loss per share was $0.07 against $0.11 a year ago. Non-GAAP net loss from continuing operations, as adjusted was $14,639,000 against $18,795,000 a year ago. Non-GAAP EBITDA was $18,441,000 against loss of $11,553,000 a year ago. Non-GAAP adjusted EBITDA was $19,817,000 against $12,225,000 a year ago.

For the six months, the company net sales of $356,884,000 against $340,007,000 a year ago. Operating loss was $18,391,000 against $65,062,000 a year ago. Loss from continuing operations before income taxes was $56,343,000 against $86,811,000 a year ago. Net loss from continuing operations was $57,667,000 against $82,223,000 a year ago. Net loss was $99,861,000 against $277,358,000 a year ago. Net loss from continuing operations per basic and diluted share was $0.55 against $0.80 a year ago. Net loss per basic and diluted share was $0.96 against $2.70 a year ago. Adjusted non-GAAP loss was $16,472,000 against $19,434,000 a year ago. Adjusted non-GAAP loss per share was $0.16 against $0.19 a year ago. Non-GAAP net loss from continuing operations, as adjusted was $30,868,000 against $33,375 a year ago. Non-GAAP EBITDA was $21,711,000 against loss of $21,872,000 a year ago. Non-GAAP adjusted EBITDA was $37,988,000 against $25,217,000 a year ago.

The company remains confident in full-year 2017 revenue guidance of $755 million to $765 million and full-year adjusted EBITDA guidance of $78.5 million to $85.5 million. The company continues to anticipate non-GAAP adjusted loss per share from continuing operations, including share-based compensation for full-year 2017 of $0.33 to $0.26 per diluted share.